Floatz logo
Floatz Rating
CCC55/100
Confidence
Indicative
v0.2
Sponsor
Regeneron Pharmaceuticals
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06787612CT.gov
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
—Recruiting———
NCT05187338CT.gov
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
—Recruiting———
NCT04611126CT.gov
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
—Terminated———
NCT04590326CT.gov
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
—Recruiting———
NCT03907852CT.gov
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
—Active Not Recruiting———
NCT03508570CT.gov
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
—Completed———
NCT03564340CT.gov
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
—Recruiting———
NCT03355976CT.gov
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
—Active Not Recruiting———
NCT03342417CT.gov
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
—Terminated———
NCT03287674CT.gov
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
—Completed———
Show 1 more trial
NCT01611558CT.gov
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Ovarian Cancer

AssetSponsorPhaseRating
Ipilimumab (this asset)Regeneron PharmaceuticalsP2CCC · 55
Tisotumab VedotinSeagen Inc.P2BB
TILInge Marie SvaneP2BB
OlaparibShandong UniversityP4BB
Cis-Diamminedichloroplatinum IiKalinski, Pawel, MD, PhDP3BB
AdriamycinGenmabP3BB
CarboplatinFudan UniversityP4BB
OTL-38On Target Laboratories, LLCP4BB
IrinotecanARCAGY/ GINECO GROUPP4BB

+42 more in the Ovarian Cancer cohort

Other indications for Ipilimumab

IndicationSponsorPhaseRating
Metastatic Neoplasm—P3BB · 71
Melanoma—P4BB · 69
Cutaneous Melanoma—P3BB · 69

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Ipilimumab in Ovarian Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/ipilimumab-ovarian-cancer

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →